Tango Therapeutics Inc.
TNGXHeld by 16 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying16 funds opened new positions. Next phase2 readout (TNG260): Jan 2026. Short interest: 26.7% of float.
Held by 16 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying16 funds opened new positions. Next phase2 readout (TNG260): Jan 2026. Short interest: 26.7% of float.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.